See every side of every news story
Published loading...Updated

Media Update: Once-weekly ALTUVIIIO® Approved in Canada for the Treatment of Adults, Adolescents and Children Living with Hemophilia A - Life Sciences British Columbia

Summary by lifesciencesbc.ca
ALTUVIIIO® is a  high-sustained factor VIII replacement therapy which provides  effective bleed protection in adults, adolescents and children with hemophilia A Approval marks a paradigm shift in the hemophilia treatment landscape and recognizes  a commitment to delivering innovation TORONTO, ON – Health Canada has issued Notice of Compliance (NOC) for ALTUVIIIO® (Antihemophilic Factor VIII [Recombinant, B-Domain deleted], Fc-VWF-XTEN fusion pro…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

lifesciencesbc.ca broke the news in on Monday, March 31, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.